Myovant Sciences Ltd (MYOV) Receives Consensus Rating of “Hold” from Analysts

Myovant Sciences Ltd (NYSE:MYOV) has been assigned an average recommendation of “Hold” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $31.00.

Several research analysts have commented on the company. Zacks Investment Research downgraded Myovant Sciences from a “hold” rating to a “sell” rating in a research note on Thursday, November 15th. Citigroup cut their target price on Myovant Sciences from $44.00 to $42.00 and set a “buy” rating for the company in a research note on Monday. Cowen restated a “buy” rating on shares of Myovant Sciences in a research note on Friday, November 9th. Goldman Sachs Group assumed coverage on Myovant Sciences in a research note on Friday, October 26th. They issued a “neutral” rating and a $25.00 target price for the company. Finally, JPMorgan Chase & Co. assumed coverage on Myovant Sciences in a research note on Thursday, September 13th. They issued an “overweight” rating and a $39.00 target price for the company.

Shares of MYOV stock traded down $0.28 on Friday, hitting $19.54. 10,156 shares of the stock were exchanged, compared to its average volume of 59,461. Myovant Sciences has a one year low of $11.30 and a one year high of $27.45. The company has a debt-to-equity ratio of 0.60, a quick ratio of 3.41 and a current ratio of 3.41. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -8.11 and a beta of 0.12.

Myovant Sciences (NYSE:MYOV) last issued its earnings results on Thursday, November 8th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.06). Equities analysts predict that Myovant Sciences will post -4 EPS for the current year.

In other Myovant Sciences news, Director Mark Altmeyer purchased 3,500 shares of the company’s stock in a transaction dated Saturday, November 17th. The stock was purchased at an average price of $13.38 per share, for a total transaction of $46,830.00. Following the transaction, the director now owns 3,500 shares in the company, valued at approximately $46,830. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 3.10% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. BB Biotech AG boosted its position in shares of Myovant Sciences by 1.7% during the 3rd quarter. BB Biotech AG now owns 3,567,882 shares of the company’s stock valued at $94,727,000 after acquiring an additional 60,000 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of Myovant Sciences by 124.8% during the 3rd quarter. Janus Henderson Group PLC now owns 2,525,193 shares of the company’s stock valued at $67,044,000 after acquiring an additional 1,401,796 shares during the last quarter. Millennium Management LLC boosted its position in shares of Myovant Sciences by 79.1% during the 2nd quarter. Millennium Management LLC now owns 191,436 shares of the company’s stock valued at $4,378,000 after acquiring an additional 84,568 shares during the last quarter. Bamco Inc. NY boosted its position in shares of Myovant Sciences by 128.1% during the 3rd quarter. Bamco Inc. NY now owns 132,761 shares of the company’s stock valued at $3,525,000 after acquiring an additional 74,561 shares during the last quarter. Finally, Platinum Investment Management Ltd. boosted its position in shares of Myovant Sciences by 31.7% during the 3rd quarter. Platinum Investment Management Ltd. now owns 71,400 shares of the company’s stock valued at $1,896,000 after acquiring an additional 17,200 shares during the last quarter. Hedge funds and other institutional investors own 22.28% of the company’s stock.

About Myovant Sciences

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Further Reading: Why is the ex-dividend date different from the record date?

Analyst Recommendations for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply